<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031380</url>
  </required_header>
  <id_info>
    <org_study_id>1R43EY023122-01A1-1</org_study_id>
    <secondary_id>1R43EY023122-01A1</secondary_id>
    <nct_id>NCT02031380</nct_id>
  </id_info>
  <brief_title>iDropper Usability in Glaucoma</brief_title>
  <official_title>Improving Ophthalmic Medication Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Care Team Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Care Team Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the usability of a medication management support&#xD;
      system for glaucoma patients self-administering eye drops named iDropper. The iDropper system&#xD;
      is a home-based ocular medication management system that reminds, instructs, dispenses, and&#xD;
      records eye drop medication usage. The iDropper system will be evaluated among a cohort of&#xD;
      glaucoma subjects self-administering eye drops for 4-weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a leading cause of vision loss in the United States, impacting the lives of ~4&#xD;
      million people. Left untreated or inadequately managed, it causes blindness -- the second&#xD;
      ranking cause of blindness in the world as well as the leader among African Americans.&#xD;
      Estimates project 79.6 million glaucoma diagnoses worldwide by 2020; of these, 74% will have&#xD;
      open-angle glaucoma (OAG), which occurs virtually without symptoms. The explanation for such&#xD;
      strikingly high disease prevalence and blindness rates is partially due to the asymptomatic&#xD;
      nature of glaucoma. However, deficient adherence to glaucoma ocular hypotensive drops is a&#xD;
      significant and escalating health care problem.&#xD;
&#xD;
      Glaucoma eye drops are often the first therapeutic choice and very effective at controlling&#xD;
      intraocular pressure (IOP) to prevent eye damage. However, glaucoma is a chronic condition&#xD;
      and daily dosing regimens for medications can be complex and difficult to manage with&#xD;
      impaired vision. Consequently, adherence and persistence to glaucoma eye drop regimens over&#xD;
      time becomes quite poor. Overwhelming research brings the unwelcome conclusion that long term&#xD;
      persistence with glaucoma medication is 33-39% at one year and positively contributes to&#xD;
      blindness.&#xD;
&#xD;
      Currently, no mechanism exists for supporting and monitoring glaucoma eye drop compliance.&#xD;
&#xD;
      The purpose of this study is to evaluate the usability of a medication management support&#xD;
      system for glaucoma patients self-administering eye drops named iDropper. The iDropper system&#xD;
      is a home-based ocular medication management system that reminds, instructs, dispenses, and&#xD;
      records eye drop medication usage. The iDropper system will be evaluated among a cohort of&#xD;
      glaucoma subjects self-administering eye drops for 4-weeks.&#xD;
&#xD;
      At study conclusion usability and satisfaction assessments will be performed to evaluate&#xD;
      iDropper system performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usability questionnaire</measure>
    <time_frame>4 weeks after trial start</time_frame>
    <description>Written questionnaire assessing usability of the iDropper system by participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction questionnaire</measure>
    <time_frame>4 weeks after study start</time_frame>
    <description>Questionnaire assessing participant satisfaction with features of the iDropper system.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glaucoma, Open-Angle [C11.525.381.407]</condition>
  <arm_group>
    <arm_group_label>Open angle glaucoma - iDropper device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Open angle glaucoma - iDropper device</intervention_name>
    <description>The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.</description>
    <arm_group_label>Open angle glaucoma - iDropper device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 21 years of age;&#xD;
&#xD;
          -  Physician diagnosis of: open angle glaucoma, angle-closure glaucoma, glaucoma suspect,&#xD;
             or ocular hypertension&#xD;
&#xD;
          -  Responsible for self-administration of eye drops.&#xD;
&#xD;
          -  No surgery within the prior 3 months;&#xD;
&#xD;
          -  Able to speak and read English;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having any concurrent medical or psychiatric condition that, in the investigator's&#xD;
             opinion, may preclude participation in this study; or&#xD;
&#xD;
          -  Cognitive or visual impairment that would interfere with completing a&#xD;
             self-administered questionnaire.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Bailey, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Care Team Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Chalfin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Congdon N, O'Colmain B, Klaver CC, Klein R, Mu√±oz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):477-85.</citation>
    <PMID>15078664</PMID>
  </reference>
  <reference>
    <citation>Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7.</citation>
    <PMID>16488940</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>December 6, 2015</last_update_submitted>
  <last_update_submitted_qc>December 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Open angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

